News

September 9, 2021

Winterlight publishes review on the use of speech-based measures to detect depression in older adults

Winterlight published a new review paper in Frontiers in Psychiatry focussing on how natural language processing has been used to study depression in older adults.

Read Read More
July 27, 2021

Winterlight presents research on speech-based digital biomarkers in collaboration with Genentech

At the Alzheimer's Association International Conference, Winterlight Labs presented new research on how speech characteristics are associated with Alzheimer's Disease, in collaboration with Genentech.

Read Read More
June 4, 2021

Winterlight publishes new research comparing digital speech measures with clinical assessments

New research published in Alzheimer's Research & Therapy examines how automatically computed speech measures correlate with clinical assessments of speech in Alzheimer's Disease and Mild Cognitive Impairment.

Read Read More
April 30, 2021

Winterlight Labs partners with the Digital Medicine Society (DiMe) to drive adoption of digital health resources

Winterlight Labs participates in the Digital Medicine Society's Tour of Duty to develop resources for the adoption of digital measures in clinical research.

Read Read More
April 29, 2021

Winterlight presents new research on speech as an objective measure of anxiety at the SOBP annual conference

Winterlight presented a poster at the SOBP annual conference exploring the use of remote speech assessments to detect signs of anxiety.

Read Read More
April 7, 2021

ISCTM conference features Winterlight research on validation of automated speech assessments

Winterlight labs presented two research posters at the International Society for CNS Clinical Trials and Methodology (ISCTM) virtual annual meeting highlighting validation studies of their automated speech assessment technology.

Read Read More
November 4, 2020

Winterlight presents new research on longitudinal speech changes in Frontotemporal Dementia at CTAD

Winterlight Labs presented two research posters at the 2020 Clinical Trials on Alzheimer's Disease (CTAD) virtual meeting, highlighting new work on longitudinal speech and language changes in Frontotemporal Dementia and Alzheimer's Disease.

Read Read More
October 20, 2020

Winterlight publishes framework and review of evaluation of speech-based biomarkers

Winterlight Labs published a paper on evaluation and validation of speech-based digital biomarkers in the journal Digital Biomarkers.

Read Read More
September 24, 2020

Winterlight is developing tools to characterize depression subtypes and symptoms based on speech

Winterlight Labs presented research on crowdsourced speech data collection for developing speech biomarkers for depression at the International Society for CNS Clinical Trials and Methodology (ISCTM) virtual autumn conference.

Read Read More
July 28, 2020

Winterlight presents new research on validation of speech-based biomarkers at the Alzheimer’s Association International Conference

Winterlight Labs presented three research posters at the 2020 virtual edition of the Alzheimer's Association International Conference (AAIC), highlighting recent validation of speech-based biomarkers for Alzheimer's disease.

Read Read More
March 18, 2020

Vivoryon partners with Winterlight for upcoming clinical trial

Vivoryon Therapeutics will use the Winterlight speech assessment in upcoming Phase 2b clinical trial of PQ912 in Alzheimer’s Disease.

Read Read More
February 26, 2020

Winterlight research accepted to NAACL 2019

The paper was accepted to "Detecting Cognitive Impairments by Agreeing on Interpretations of Linguistic Features" to NAACL. NAACL is a top-tier conference in computational linguistics and artificial intelligence that will be hosted in Minneapolis, USA in early June.

Read Read More
February 20, 2020

Winterlight presents new findings on speech changes in Alzheimer’s at ISCTM 2020

Winterlight presented new research from a longitudinal study of Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) today at the 16th Annual Meeting of the International Society for CNS Clinical Trials and Methodology.

Read Read More
January 7, 2020

Pear Therapeutics licenses Winterlight technology

Winterlight Labs has entered into an agreement with Pear Therapeutics to develop speech-based biomarkers to improve the efficacy of prescription digital therapeutics.

Read Read More
December 4, 2019

Winterlight presents updates on speech-based digital biomarker development at CTAD 2019

Today at the Clinical Trials for Alzheimer’s Disease (CTAD) Conference, Winterlight presented preliminary data on a speech-based language composite score for Frontotemporal Dementia and improved tracking of cognitive decline in Healthy Seniors.

Read Read More
November 18, 2019

Winterlight Labs raises $5.6M in series A funding in round led by Hikma Ventures

Hikma Pharmaceuticals PLC announces that its venture capital arm, Hikma Ventures has led a CAD 5.6 million oversubscribed round of financing for Winterlight Labs Inc. with participation from First Star Ventures, Pacific Health Ventures, existing investor Grey Sky Venture Partners and other investors.

Read Read More
August 13, 2019

Winterlight Labs featured in The Wall Street Journal

The Wall Street Journal published an article titled "What Your Voice Reveals About You" about the ability of the voice-based AI to identify individuals in the realm of fraud prevention and medicine. Winterlight Labs was featured as an example of speech being used to detect dementia such as Alzheimer’s.

Read Read More
July 9, 2019

Winterlight is developing speech-based digital biomarkers to monitor disease progression in patients with FTD in collaboration with Alector

Winterlight announced today it is developing vocal biomarkers for monitoring disease progression in frontotemporal dementia (FTD) patients in collaboration with Alector, a biotechnology company developing therapeutics for neurodegeneration.

Read Read More
May 18, 2019

Winterlight predicts cognitive status using 2 minutes of speech

At the 74th Annual Meeting of the Society for Biological Psychiatry, Winterlight is presenting a poster highlighting the use of verbal picture descriptions to predict cognitive status. Using data from 219 individuals who described a picture in their own words, we were able to estimate an individual’s score on the Montreal Cognitive Assessment (MoCA) within 2.6 points (8.7% error).

Read Read More
February 21, 2019

Winterlight Labs’ Liam Kaufman quoted in The New York Times

The New York Times published an article which describes how emerging AI technologies might transform patient care, by detecting diseases earlier and indicating whether drug treatments are working in real-time. Winterlight Labs and its technology are featured here to demonstrate the potential of voice analysis in detecting and treating clinical conditions.

Read Read More
February 6, 2019

Battling Dementia with the Power of AI

Winterlight Labs was featured on TVO's The Agenda with Steve Paikin. The episode titled "Battling Dementia with the Power of AI" showcases Winterlight Lab's partnership with Revera Living.

Read Read More
January 7, 2019

Winterlight Labs, Inc. Enters Collaboration with Johnson & Johnson Innovation to Develop a Digital Biomarker for Diagnosis of Early Stage Alzheimer's Disease

The agreement was facilitated by Johnson & Johnson Innovation LLC. The collaboration will initially focus on developing a sensitive digital biomarker that can distinguish patients with mild cognitive impairment, an early stage of Alzheimer's Disease (AD), from healthy elderly subjects.

Read Read More
November 30, 2018

Winterlight research accepted to NeurIPS 2018 workshops

Two of our research papers were accepted and will be presented at NeurIPS (the conference previously known as NIPS) workshops next week in Montreal. NeurIPS is the leading machine learning conference - tickets sold out in 20 minutes.

Read Read More
October 25, 2018

Winterlight technology shows positive results of treatment in Phase 1 study of Cortexyme's COR388 in Alzheimer’s disease

No significant improvements were observed in Mini Mental State Examination (MMSE) scores or CANTAB measures of cognition between treatment (COR388) and placebo groups. In contrast, Winterlight’s cognitive assessment showed statistically significant improvements from baseline to endpoint in the treatment group, with no such differences seen in the placebo group.

Read Read More
August 25, 2018

Winterlight Labs secures additional seed funding ($1,000,000) from American investors to commercialize speech-based detection of cognitive impairments

Winterlight Labs has closed $1,000,000 in additional seed funding from Grey Sky Venture Partners (GSVP), based on Bellevue Washington. In total, Winterlight Labs has raised $1.5 million.

Read Read More
January 25, 2018

Winterlight Labs is featured on CTV News, discussing its partnership with Revera

Winterlight will be piloting its speech-based cognitive assessment at one of Revera's senior care homes in Toronto with 50 participants over a 6 month period. This pilot was funded via the Ontario Centres of Excellence (OCE) Health Technology Fund (HTF).

Read Read More
January 25, 2017

Winterlight Labs' Co-founder Liam Kaufman interviewed on Fairchild TV’s Timeline Magazine

Liam Kaufman describes how the technology works and gives a demonstration of the app.

Read Read More
January 23, 2017

Winterlight Labs secures seed funding to commercialize speech-based detection of cognitive impairments

Winterlight Labs closed the first tranche of $500,000 in seed funding from Novatio Ventures, an early stage life sciences investment firm.

Read Read More
January 9, 2017

Winterlight Labs’ Frank Rudzicz quoted in Wired Magazine

Winterlight Co-founder Frank Rudzicz explains how the technology works in Wired Magazine.

Read Read More
January 5, 2017

Winterlight Labs participants in a J&J Feasibility Study

The research will evaluate Winterlight's proprietary technology for analyzing voice samples obtained from Janssen Research & Development's ongoing clinical trials in Alzheimer's and neurodegenerative diseases.

Read Read More
July 26, 2016

Winterlight Labs wins international AGE-WELL startup competition

Winterlight Labs has won the AGE-WELL Pitch Competition: Technology to Support People with Dementia. Ten teams from Canada and around the world competed in the AGE-WELL Pitch Competition.

Read Read More
July 14, 2016

Wintelight Labs “Graduates” from the Rotman Creative Destruction Lab

Winterlight Labs has graduated from the Rotman Business School’s Creative Destruction Lab (CDL). The CDL works with startups that employ innovations in technology and business models that promise a chance of delivering massive improvements to economic productivity and human welfare.

Read Read More
December 11, 2015

Winterlight Labs Co-founders publish ground-breaking research on dementia and Alzheimer's Disease detection using natural language

Winterlight co-founders Katie Fraser, Frank Rudzicz, and Winterlight scientific advisor Jed Meltzer have discovered how to diagnose Alzheimer's disease with more than 82 per cent accuracy by evaluating the interplay between four linguistic factors.

Read Read More